Senescence of the Kidney

2019 ◽  
pp. 39-48
Author(s):  
Eoin D. O’Sullivan ◽  
David A. Ferenbach
Keyword(s):  
Chronic Kidney Disease ◽  
Dna Damage ◽  
Kidney Disease ◽  
Growth Arrest ◽  
Cell Stress ◽  
Renal Protection ◽  
Functional Changes ◽  
The Face ◽  
Renal Aging

Senescence is a state of terminal growth arrest, with associated structural and functional changes in the affected cell. Cellular senescence can be induced in embryogenesis and in response to stimuli including aging, DNA damage, and cell stress. There is great interest in the physiological function and pathological role of senescent cells in the progression of the renal aging phenotype and chronic kidney disease. This chapter will explore the incomplete but evolving knowledge of the roles for senescence in the developing, injured, aged, and scarred kidneys. The potential for senescent cells to be targeted to maximize renal protection in the face of aging and injury will also be summarized.

scholarly journals Renal protection of rhein against 5/6 nephrectomied‐induced chronic kidney disease: role of SIRT3‐FOXO3α signalling pathway

2020 ◽  
Vol 72 (5) ◽  
pp. 699-708 ◽  
Author(s):  
Xiaoxiao Wu ◽  
Meiyou Liu ◽  
Guo Wei ◽  
Yue Guan ◽  
Jialin Duan ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Signalling Pathway ◽  
Renal Protection

Levels of DNA damage (Micronuclei) in patients suffering from chronic kidney disease. Role of GST polymorphisms

2018 ◽  
Vol 836 ◽  
pp. 41-46 ◽  
Author(s):  
Susana Pastor ◽  
Lara Rodríguez-Ribera ◽  
Zuray Corredor ◽  
Miguel Inácio da Silva Filho ◽  
Kari Hemminki ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Dna Damage ◽  
Kidney Disease ◽  
Gst Polymorphisms

Potential effect of pharmaceutical care to improve outcomes in patients with chronic kidney disease-mineral bone disorder in Sulaimani dialysis centers

2020 ◽  
pp. 82-94
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Pharmaceutical Care ◽  
Biochemical Parameters ◽  
Positive Impact ◽  
Potential Effect ◽  
Care Group ◽  
Mineral Bone Disorder ◽  
Bone Disorder

Objective: the present study was aimed to evaluate the role of pharmaceutical services in improving the outcome of mineral bone disorder in patients with advanced chronic kidney disease. Methodology: One hundred and twenty patients with chronic kidney disease-mineral bone disorder (CKD-MBD) screened for eligibility, seventy-six patients enrolled in the study and randomly allocated into two groups: pharmaceutical care and usual care, both groups interviewed by the pharmacist using specific questionnaire for assessing the quality of life (QoL). All the drug related problems (DRPs) including drug-drug interactions (DDIs) were recorded by the pharmacist. Blood samples were collected and utilized for analyzing the levels of vitamin D, phosphorous, calcium, albumin and parathyroid hormone at baseline and three months after. The pharmaceutical care group received all the educations about their medications and how to minimize DRPs; improve the QoL. Additionally, the pharmaceutical intervention included correcting the biochemical parameters. Results: Pharmaceutical care significantly improved patients QoL and minimized DRPs and DDIs. It was also effective in improving the biochemical parameters. Conclusion: Pharmaceutical care has a positive impact on improving the outcome of patients with CKD-MBD through attenuating DRPs, improving the biochemical parameters and the QoL.

Sign in / Sign up

Export Citation Format

Share Document